Sparks commentary - SynAct Pharma

Healthcare

Sparks - SynAct Pharma

More on this equity
SynAct Pharma (STO:SYNACT) – latest SEK50m Fenja drawdown extends funding headroom
Published by Jyoti Prakash, CFA

SynAct Pharma has drawn down the remaining SEK50m under its convertible financing facility with Fenja Capital, bringing total utilisation to SEK100m. The additional funding strengthens SynAct’s liquidity position and provides greater financial flexibility to advance resomelagon’s clinical development, particularly preparations for Phase III in rheumatoid arthritis and ongoing partnering discussions. The new convertibles carry a conversion price of SEK24.60/share, matching the initial tranche, with the full facility maturing in December 2027. Full conversion would result in c 6.74% shareholder dilution. Management had previously guided to cash headroom into Q427, which we understand already accounted for this latest cash inflow.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.